Literature DB >> 26968331

Dose site reactions and related findings after vaccine administration in safety studies.

Paul Baldrick1.   

Abstract

Potential new human vaccines undergo toxicology testing to evaluate local reactogenicity and systemic toxicity. A review of 30 recently published and in-house repeat dose toxicity studies with a variety of vaccines was performed. Species tested were generally rat or rabbit, usually by intramuscular (although occasionally subcutaneous) injection. Results showed no unexpected findings indicating vaccine toxicity, but classic signs of enhanced acute and/or chronic inflammation at the dose site compared with that seen in injected control animals, often accompanied by changes in draining lymph nodes and the spleen (lymphoid hyperplasia and/or increased weight). Other associated signs of a response to vaccine dosing were altered clinical pathology parameters (commonly raised blood neutrophil count and altered globulin level). No obvious difference in dose site or systemic reaction was seen across vaccine, species or the dose route used. A non-dose recovery period of 2 to 4 weeks was sufficient to show evidence of reversibility of dose site effects. Injection site, lymphoid tissue and clinical pathological changes can be interpreted as related to an expected reaction after vaccine dosing, with generation of an immune response largely as a result of the presence of adjuvant, although direct vaccine antigen involvement was also occasionally demonstrated by the presence of a slightly increased inflammatory response seen over adjuvant treatment only. Overall, the need for toxicity testing of vaccines is in line with current regulatory guideline requirements and has proven to be a valuable part of the safety evaluation process prior to human use.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  adjuvant; dose site; injection reactions; toxicology testing; vaccine

Mesh:

Substances:

Year:  2016        PMID: 26968331     DOI: 10.1002/jat.3314

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  6 in total

1.  Development of COVID-19 therapies: Nonclinical testing considerations.

Authors:  Paul Baldrick
Journal:  Regul Toxicol Pharmacol       Date:  2022-05-21       Impact factor: 3.598

2.  A novel vaccine adjuvant based on straight polyacrylate potentiates vaccine-induced humoral and cellular immunity in cynomolgus macaques.

Authors:  Vincent Pavot; Hélène Bisceglia; Florine Guillaume; Sandrine Montano; Linong Zhang; Florence Boudet; Jean Haensler
Journal:  Hum Vaccin Immunother       Date:  2021-01-10       Impact factor: 3.452

3.  Preliminary nonclinical safety and immunogenicity of an rVSV-ΔG-SARS-CoV-2-S vaccine in mice, hamsters, rabbits and pigs.

Authors:  Noa Madar-Balakirski; Amir Rosner; Sharon Melamed; Boaz Politi; Michal Steiner; Hadas Tamir; Yfat Yahalom-Ronen; Elad Bar-David; Amir Ben-Shmuel; Assa Sittner; Itai Glinert; Shay Weiss; Erez Bar-Haim; Hila Cohen; Uri Elia; Hagit Achdout; Noam Erez; Shahar Rotem; Shlomi Lazar; Abraham Nyska; Shmuel Yitzhaki; Adi Beth-Din; Haim Levy; Nir Paran; Tomer Israely; Hadar Marcus
Journal:  Arch Toxicol       Date:  2022-01-15       Impact factor: 5.153

4.  Evaluation of the AV7909 Anthrax Vaccine Toxicity in Sprague Dawley Rats Following Three Intramuscular Administrations.

Authors:  Veena V Rao; C Steven Godin; Michael J Lacy; Jon R Inglefield; Sukjoon Park; Bruna Blauth; Joshua J Reece; Boris Ionin; Vladimir Savransky
Journal:  Int J Toxicol       Date:  2021-07-19       Impact factor: 2.032

5.  Preclinical safety and immunological efficacy of Alternaria alternata polymerized extracts.

Authors:  María Morales; María T Gallego; Victor Iraola; Raquel Moya; Soraya Santana; Jerónimo Carnés
Journal:  Immun Inflamm Dis       Date:  2017-12-19

6.  Nonclinical safety assessment of repeated administration and biodistribution of ChAd3-EBO-Z Ebola candidate vaccine.

Authors:  Camille Planty; Guillaume Chevalier; Marie-Ève Duclos; Clémentine Chalmey; Catherine Thirion-Delalande; Cécile Sobry; Ann-Muriel Steff; Eric Destexhe
Journal:  J Appl Toxicol       Date:  2020-01-21       Impact factor: 3.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.